Phaseline

Targets › BCL-XL

BCL-XL: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Open in Phaseline: the race on BCL-XL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ascentage Pharma GroupAPG-3288
Dual BCL-2 and MCL-1 inhibitor
BCL2, MCL1, BCL-XLPhase 1Relapsed/Refractory Hematological MalignanciesDec 2029

Conditions

Relapsed/Refractory Hematological Malignancies (1)

Modalities

small molecule (1)

Companies

Ascentage Pharma Group (1)

Related targets

BCL2 (1) MCL1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.